Additional Positive Data from Phase 1 of BEXMAB
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML Company announcement, 18 March 2024 at 7:00 a.m. GMT / 9:00 a.m. EET Key highlights - Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. - 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. -